Agitation/aggression is one of the most common and serious behavioral complications of dementia. If the behavior is refractory to standard care (behavior approaches and off label use of psychotropic medications), other evidence based treatment options are not currently available. Retrospective reviews and preliminary studies have indicated Electroconvulsive Therapy (ECT) may be a safe, effective intervention in this patient population. This study will measure the impact of open-label ECT on symptoms of agitation, aggression, cognition, mood and psychosis for patients referred for ECT who accept this intervention vs. those patients referred for ECT but decline this intervention (i.e. standard care controls). It will also assess adverse events, activities of daily living and caregiver burden during study participation. The hypothesis is that subjects with dementia related aggression/agitation who receive ECT will show significantly greater reductions in these behaviors than subjects who do not consent for ECT and continue with standard care. Pine Rest is partnering with McLean Hospital (Massachusetts) to answer this question. To our knowledge, this is the first prospective study to examine whether patients receiving ECT or standard care differ in reduction of aggression and agitation symptom severity and changes in cognition pre- and post- treatment.
Study Type
OBSERVATIONAL
Enrollment
23
The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
McLean Hospital
Belmont, Massachusetts, United States
Older Adult Unit of Pine Rest Christian Mental Health Services
Grand Rapids, Michigan, United States
Change in baseline of the Cohen-Mansfield Agitation Inventory Short Version (CMAI)
Measures agitation or aggression outcomes - completed by primary caregiver
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Severe Impairment Battery (SIB)
Gathers direct performance-based data from the subject with dementia on a wide variety of low-level tasks that take into account the specific behavioral and cognitive deficits associated with severe dementia
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Cornell Scale for Depression in Dementia (CSDD)
Assesses the presence and severity of depressive symptoms - completed by primary caregiver
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Neuropsychiatric Inventory Nursing Home Version (NPI)
Measures neuropsychiatric symptoms outcomes and caregiver burden - completed by primary caregiver
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Clinical Global Impression Scale: Severity (CGI-S)
Indicates severity of dementia with agitation/aggression at the time of assessment - completed by physician
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Mini Mental Status Examination (MMSE)
Measures cognition - primary caregiver completes with subject
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Wechsler Adult Intelligence Scale 4th Edition (WAIS-IV) Digit Span (forwards and backwards)
Measures concentration, attention and memory - primary caregiver completes with subject
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Geriatric Evaluation of Mental Status (GEMS)
Measures list learning tasks to assess verbal memory outcome - primary caregiver completes with subject
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)
Measures functional ability outcomes - completed by primary caregiver
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Use of Psychoactive "As Needed" (PRN) Medication
Records use of PRN medication for agitation/aggression
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
Delirium and/or adverse reactions to ECT or medication
Assessed by treating physician
Time frame: Participants will be followed on the average of 5 weeks (+/- 1 week) since ECT treatment is generally administered 3x per week for 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.